How Long Can This Pharma Gold Rush Last?

In the following video, Brenton Flynn sits down with Fool.com analyst Brendan Byrnes to discuss a topic that's gathered considerable attention in recent years: orphan drug development. In particular, they discuss the reasons for this focus, as well as an interesting scenario in which a very small patient market has become saturated with options.

The future of MannKind?
While diabetes is far from an orphan disease, there's one company pursuing something extraordinary in the space. Will MannKind's disruptive technology revolutionize the way diabetes is treated around the world -- or will the FDA put the kibosh on this product before it even hits the market? In a new premium research report on MannKind, these complex issues are made crystal clear, in addition to showing you why to buy or sell the stock today. To find out more -- and get a full year of free updates -- click here to grab your copy today.


The article How Long Can This Pharma Gold Rush Last? originally appeared on Fool.com.

Brendan Byrnes and The Motley Fool have no position in any stocks mentioned. Brenton Flynn owns shares of Sarepta Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Introduction to Preferred Shares

Learn the difference between preferred and common shares.

View Course »

Basics Of The Stock Market

Stock Market 101 - everything you need to know but were afraid to ask!

View Course »

Add a Comment

*0 / 3000 Character Maximum